Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications

Table 7 Telaprevir

Ref.	n	Design	Treatment	Population	Outcome
Hézode et al[73]	334	Phase 2 randomized clinical trial	Telaprevir PEGIFN/RBV	HCV genotype 1 - treatment naïve	Telaprevir groups had significantly higher rates of SVR than PEGIFN/RBV alone. Depression occurred in 20%-23% of patients and was not significantly different across groups
McHutchison et al[68]	115	Randomized clinical trial	Telaprevir	HCV genotype 1 - previous non-responders to PEGINF/RBV	Re-treatment with telaprevir was more effective than PEGIFN-α/RBV alone. Depression occurred in 11%-17% of participants
Zeuzem et al[69]	663	Phase III randomized clinical trial	Telaprevir, PEGIFN- α-2a/ RBV	HCV genotype 1 - previous non responders, partial responders and relapsers	Telaprevir in combination with PEGIFN/RBV significantly improved rates of SVR and, as compared with PEGIFN/RBV alone showed no increase in neuropsychiatric side effects
Kumada et al[72]	1126	Multicenter randomized clinical trial	Telaprevir, PEGIFN-α-2b/RBV	HCV genotype 1 - treatment naive	Triple therapy with telaprevir-based regimen resulted in higher SVR with shorter duration. Depression was not listed as an adverse event
Sherman et al[74]	540	Randomized clinical trial	Telaprevir PEGIFN-α-2a/RBV	HCV genotype 1 - treatment naïve	Combination therapy with telaprevir for 24 wk was non inferior to standard therapy for 48 wk. Fifty-three percent of patients experienced psychiatric symptoms

PEGIFN: Pegylated interferon (peginterferon); RBV: Ribavirin; HCV: Hepatitis C virus; SVR: Sustained virologic response.